The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit https://www.globenewswire.com/Tracker?data=33tu6f4Da0hunBBzDlnINlhG4-YsNAE1MAAnDFccCifn4P0j7VFxykKlfH7baRoqFEB9S-d_rlOk8ysITbkJJg== www.roche.com. All trademarks used or mentioned in this release are protected by law. *Production capacities are combined for both the SARS-CoV-2 Rapid Antigen Test (nasopharyngeal) and the new SARS-CoV-2 Rapid Antigen Test Nasal References [1] OASH Nasal Specimen Collection Fact Sheet - Updates 2020-11-11 https://www.globenewswire.com/Tracker?data=glfQdGQPq3a6nGsHHjIZ6LDMf9-rSlW59aDwFVmA9fotp35gdTu5iiCpA46cW1vH9ymaKTDYFLr8l_RIjE3q-CUII68X7RxPF7Uzp-za2lLcWkdKEMcRDMzbZ263JRA1YZP4azyyt-cpcY19Iat1SM-H-0K9ZFV-OBjm4ITweC1yk2_HwR4_QL1ZHRQUxjfTmhNBbec_q1Zlgx9DBuOE4OOQHh0OnVVbIuIHRV9o60lWC6MpaMHSw-t_ByFTDGWB3_AK97ROQIJhkF9ACcX89Hp94rwAPYWTIMSIlU3YrJc= [2] SD Biosensor. (2020). SARS-CoV-2 Rapid Antigen Test Nasal package insert [3] European Centre for Disease Prevention and Control. Diagnostic testing and screening for SARS-CoV-2. 2020. [4] Cerutti, Krüger, van Beek, Igloi, Krüttgen, Salvagno Roche Group Media Relations Phone: +41 61 688 8888 / e-mail: https://www.globenewswire.com/Tracker?data=3xcRqDVUc7CsNS9oAb1WfNM3QdxDbYMHKImS-MOEnIyelLV2FbpgczfHL3S3FmOEO6VN7kbps0WhwXkIjpLBwtljqsrhxP1CmXnXarsV7P2SQnCGTS-oZgnFTEF-DWRp media.relations@roche.com Dr. Nicolas Dunant Patrick Barth Phone: +41 61 687 05 17 Phone: +41 61 688 44 86 Dr. Daniel Grotzky Karsten Kleine Phone: +41 61 688 31 10 Phone: +41 61 682 28 31 Nina Mählitz Nathalie Meetz Phone: +41 79 327 54 74 Phone: +41 61 687 43 05 Dr. Barbara von Schnurbein Phone: +41 61 687 89 67 Roche Investor Relations Dr. Karl Mahler Jon Kaspar Bayard Phone: +41 61 68-78503 Phone: +41 61 68-83894 e-mail: mailto:karl.mahler@roche.com e-mail: mailto:jon_kaspar.bayard@roche.com karl.mahler@roche.com jon_kaspar.bayard@roche.com -------------------------------------------- ------------------------------------------- Dr. Sabine Borngräber Dr. Bruno Eschli Phone: +41 61 68-88027 Phone: +41 61 68-75284 e-mail: mailto:sabine.borngraeber@roche.com e-mail: mailto:bruno.eschli@roche.com sabine.borngraeber@roche.com bruno.eschli@roche.com -------------------------------------------- ------------------------------------------- Dr. Birgit Masjost Dr. Gerard Tobin Phone: +41 61 68-84814 Phone: +41 61 68-72942 e-mail: mailto:birgit.masjost@roche.com e-mail: mailto:gerard.tobin@roche.com birgit.masjost@roche.com gerard.tobin@roche.com -------------------------------------------- ------------------------------------------- Investor Relations North America Loren Kalm Dr. Lisa Tuomi Phone: +1 650 225 3217 Phone: +1 650 467 8737 e-mail: mailto:kalm.loren@gene.com e-mail: mailto:tuomi.lisa@gene.com kalm.loren@gene.com tuomi.lisa@gene.com -------------------------------------------- ------------------------------------------- Attachment -- 01022021_MR_ Rapid Ag Nasal test_ EN https://ml-eu.globenewswire.com/Resource/Download/b4f29e20-3519-4f4a-baff-b98919544be9
(END) Dow Jones Newswires
February 01, 2021 11:25 ET (16:25 GMT)